Aims We report the cerebrospinal fluid opening pressure (CSF-OP) measurements obtained before and after venous sinus stenting (VSS) in 50 patients with idiopathic intracranial hypertension.
Methods The CSF-OP was measured with a spinal tap 3 months before and 3 months after treatment. All data were prospectively collected and included patient demographics, weight (kg), body mass index (BMI), acetazolamide daily dosage (mg), procedural details, complications, venous sinus pressures (mm Hg), trans-stenotic pressure gradient (mm Hg), transverse sinus symmetry, and type of venous sinus stenosis.
Results The average pretreatment CSF-OP was 37 cm H2O (range 25–77) and the average post-treatment CSF-OP was 20.2 cm H2O (range 10–36), with an average reduction of 16.8 cm H2O (P<0.01). The post-treatment CSF-OP was less than 25 cm H2O in 40/50 patients. The average acetazolamide daily dose decreased from 950 mg to 300 mg at the time of 3-month follow-up (P<0.01). No patient required an increase in acetazolamide dose 3 months after VSS. The average weight before treatment was 95.4 kg with an average BMI of 35.41. There was an average increase in body weight of 1.1 kg at the 3-month follow-up with an average increase in BMI of 0.35 (P=0.03).
Conclusions We provide evidence that there is a significant decrease in CSF-OP in patients with idiopathic intracranial hypertension 3 months after VSS, independent of acetazolamide usage or weight loss.
- intracranial pressure
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Contributors AP: Substantial contributions to the conception and design, acquisition, analysis, and interpretation of data; guarantor of the paper. CO: Substantial contributions to the conception and design; critical revision of the manuscript for important intellectual content. JW: Acquisition of data. KB: Acquisition of data. KG: Statistical analysis and interpretation. YPG: Substantial contributions to the conception and design of the work; critical revision of the manuscript for important intellectual content. MD: Substantial contributions to the conception and design of the work; critical revision of the manuscript for important intellectual content.
Funding KG: This work was supported by Clinical and Translational Science Center at Weill Cornell Medical College grant number (1-UL1-TR002384-01).
Competing interests Dr Gobin is the founder, medical director and CEO of Serenity Medical None declared.
Patient consent Not required.
Ethics approval Weill Cornell Medicine IRB.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Unprocessed data are available upon request from the corresponding author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.